References
- Fisman D H, Lipsitch M, Hook E W, Goldie S J. Projection of the future dimensions and costs of the genital herpes simplex virus type 2 epidemic in the United States. Sex Transm Dis 2002; 29: 608–622
- Vetsika E K, Callan M. Infectious mononucleosis and Epstein-Barr virus. Expert Rev Mol Med 2004; 5: 1–16
- Lehtinen M, Kaasila M, Pasanen K, et al. Seroprevalence ATLAS of infections with oncogenic and nononcogenic human papillomaviruses in Finland in the 1980's and 1990's. Int J Cancer 2006; 119: 2612–2619
- Mårdh P A. Aetiology, diagnosis and therapy of sexually transmitted and allied infections—reflections on novel observations and current trends. Eur J Contracept Reprod Health Care 2006; 11: 169–174
- Arvaja M, Lehtinen M, Koskela P, et al. Serological evaluation of herpes simplex virus type 1 and type 2 infections in pregnancy. Sex Transm Infect 1999; 75: 168–171
- Hiltunen-Back E, Reunala T, Haikala O, et al. Occurrence of C. trachomatis infection in Finland. Sex Transm Dis 2003; 31: 737–741
- Health Protection Agency, SCIEH, ISD, National Public Health Service for Wales, CDSC Northern Ireland and the UASSG. Renewing the focus. HIV and other sexually transmitted infections in the United Kingdom in 2002, , et al. HPA, London 2003
- Laukkanen P, Koskela P, Pukkala E, et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 2003; 84: 2105–2109
- Auvinen E, Niemi M, Malm C, et al. High prevalence of HPV among female students in Finland. Scand J Infect Dis 2005; 37: 873–876
- Nahmias A J. Neonatal HSV infection part II. Obstetric considerations—a tale of hospitals in two cities. Herpes 2004; 11: 41–44
- Hjallgrim H, Askiling J, Rostgaard K, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 2003; 349: 1324–1332
- IARC. Human papillomaviruses. IARC, Lyon 1996, IARC Monographs 63
- Paavonen J, Eggert-Kruse W. Chlamydia trachomatis: impact on human reproduction. Hum Reprod 1999; 5: 433–450
- Anttila T, Saikku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk for cervical squamous cell carcinoma. JAMA 2001; 285: 46–51
- Crawford D H, Macsween K F, Higgins C, et al. A cohort study among university students: identification of risk factors for Epstein–Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis 2006; 43: 276–282
- Weiner R L, Lee S L, Hughes J P, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of university students. N Engl J Med 2003; 157: 218–226
- Koutsky L A, Harper D M. Current findings from prophylactic HPV vaccine trials. Vaccine 2006; S24: 114–121
- Stanberry L, Spruance S L, Cunningham L, et al. Glycoprotein D adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347: 1652–1661
- Lehtinen M, Apter D, Dubin G, et al. Enrolment of 22,000 adolescent women to passive, population-based cancer registry follow-up of long term human papillomavirus vaccine efficacy. Int J STD & AIDS 2006; 17: 517–521
- Hague T, Johanssen I, Donbagoda E, et al. A mouse monoclonal antibody against EBV envelopes glycoprotein 350 prevents infections both in vitro and in vivo. J Infect Dis 2006; 194: 584–587
- Pebody R, Andrews N, Brown D, et al. The seroepidemiology of herpes simplex virus (HSV) type-1 and -2. Sex Transm Infect 2005; 80: 185–191
- Miller W C. Screening for chlamydial infection: are we doing enough?. Lancet 2005; 365: 456–458
- Mcleod J, Salisbury C, Low N, et al. Coverage and uptake of systematic postal screening for genital Chlamydia trachomatis and prevalence of infection in the United Kingdom general population: a cross-sectional study. BMJ 2005; 330: 940
- Viner R M, Barker M. Young people's health: the need for action. BMJ 2003; 330: 901–903
- Garnett G P. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005; 191: 97–106